NRG Oncology has selected healthcare artificial intelligence (AI) company Pieces for its FORTE study to expedite eligible subject identification for colorectal cancer prevention trial.
Pieces will extract approved data from clinical notes by employing the analytics engine that uses Natural Language Processing (NLP) and AI, Pieces Predict.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pieces Predict will also extract data from records to help identify qualified participants for the study.
Leveraging Pieces’ AI and NLP technologies, the FORTE study of NRG Oncology will modernise the clinical trial process by automating the search for eligible participants.
The study’s primary objective is to determine when people with one or two small benign polyps removed during colonoscopy should have their repeat exam.
It is expected to enroll 9,500 participants. This requires identifying and engaging enough number of eligible subjects from US sites.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUsing Pieces’ technology, FORTE study sites will be able to quickly identify participants with specific clinical and non-clinical inclusion and exclusion characteristics.
Pieces founder and CEO Ruben Amarasingham said: “Pieces is providing a turn-key solution for the national study, including handling all administrative, operational, and technical aspects of partnering with select study sites on behalf of NRG Oncology for the NLP component of this work.
“As a mission-driven healthcare AI firm, we are incredibly excited to work with NRG Oncology and the select study sites to help advance colorectal cancer research and science that may help save lives.”
FORTE is being conducted through the NCI Community Oncology Research Program (NCORP) along with the National Clinical Trials Network (NCTN) members.
NRG Oncology is leading the trial with the participation of Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and SWOG.
